Kathleen Young
Psychiatric/Mental Health · Bangor, MENPI 1225372147
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Alkermes, Inc. at 54.8% of the total. Reporting peaked in 2023 at $238 and has fallen 91.1% since, to $21 in 2025.
Across 16 payments — averaging $49.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$433
- Johnson & Johnson$138
- Boehringer Ingelheim$108
- Neurocrine Biosciences, Inc.$66
- AstraZeneca$21
- AbbVie$13
- plus $12 from 1 others
What the payments were for
- Food & beverage$78299%
- Education$91%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 7 | $433 |
| Johnson & Johnson | 3 | $138 |
| Boehringer Ingelheim | 2 | $108 |
| Neurocrine Biosciences, Inc. | 1 | $66 |
| AstraZeneca | 1 | $21 |
| AbbVie | 1 | $13 |
| Abbott | 1 | $12 |
How this compares
$790 in reported general payments places this provider in the 80th percentile of 192 psychiatric/mental health providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Chlorpromazine Hcl | 26 | $3,963 |
| Memantine Hcl | 102 | $2,876 |
| Quetiapine Fumarate | 71 | $2,143 |
| Lurasidone Hcl | 18 | $1,759 |
| Atomoxetine Hcl | 15 | $1,243 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $1,235 |
| Donepezil Hcl | 182 | $1,228 |
| Naltrexone Hcl | 17 | $1,195 |
| RivastigmineRivastigmine Tartrate | 13 | $950 |
| Escitalopram Oxalate | 105 | $829 |
| Duloxetine Hcl | 14 | $785 |
| Modafinil | 12 | $784 |
| Olanzapine | 20 | $682 |
| Buspirone Hcl | 44 | $586 |
| Haloperidol | 16 | $569 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Bangor
- Bethney SeifertBangor$8K
- Joyce PetroskyBangor$2K
- Melissa CharetteBangor$1K
- Stephanie RiehlBangor$871
- Amanda DeluckBangor$847
- Ileana VintilaBangor$833
- Stacy GuayBangor$767
- Barbara WombleBangor$506
- Deborah PickeringBangor$501
- Evan MooreBangor$472
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.